1
|
Sanchez-Salvador J, Monte M, Negro C, Batchelor W, Garnier G, Blanco A. Dataset for facilitating the calculation of aspect ratio of fibrillated cellulose suspensions based on gel point data. Data Brief 2024; 52:109944. [PMID: 38293579 PMCID: PMC10827384 DOI: 10.1016/j.dib.2023.109944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 10/13/2023] [Accepted: 12/06/2023] [Indexed: 02/01/2024] Open
Abstract
This article describes data related to the research paper "Simplification of gel point characterization of cellulose nano and microfiber suspensions" [1]. The characterization of fibrillated celluloses that include cellulose nano and microfibrils (CMNFs) is a challenge for their production on an industrial scale, requiring easy techniques that control their quality and reproducibility. Gel point is a convenient parameter commonly used to estimate the aspect ratio (AR) of CMNFs. However, this estimation requires many sedimentation experiments, which are tedious and time consuming. The dataset includes all information related to the traditional experiments and to the simplified experiments for estimating gel point and AR based on only one sedimentation experiment. The full data set is useful to select the initial concentration to carry out the experimentation. This dataset also includes the information for the validation of the proposed simplified methodology and shows that the errors are lower than 7% for the gel point calculation and of 3% for the AR estimation. A larger databased of nanocellulose suspensions can be built with the reuse of this data to allow the estimation of nanocellulose properties in a future.
Collapse
|
2
|
Medel-Plaza M, Auñón A, Blanco A, García-Cañete J, Salar-Vidal L, Esteban J. Periprosthetic joint infection caused by Haemophilus parainfluenzae. Case report and literature review. REVISTA ESPANOLA DE QUIMIOTERAPIA : PUBLICACION OFICIAL DE LA SOCIEDAD ESPANOLA DE QUIMIOTERAPIA 2023; 36:325-328. [PMID: 36924032 DOI: 10.37201/req/127.2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
|
3
|
Ríos MP, López-Medina DC, Tort CG, Brandariz JR, Lema LV, Santiago-Pérez MI, Candal C, Montes A, López MJ, Dalmau R, Provencio M, Fernández E, Blanco A, Ravina AR. Mortality attributable to environmental tobacco smoke exposure in Spain in 2020. Arch Bronconeumol 2023; 59:305-310. [PMID: 36967344 DOI: 10.1016/j.arbres.2023.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 02/18/2023] [Accepted: 02/21/2023] [Indexed: 03/11/2023]
Abstract
INTRODUCTION AND OBJECTIVES Exposure to environmental tobacco smoke (ETS) is associated with increased mortality and morbidity. The objective of this study was to estimate the impact of ETS exposure in Spain on mortality in 2020 in the population aged 35 years and over. METHODS A method of estimating attributable mortality (AM) based on the prevalence of ETS exposure was applied. Prevalence data were obtained from a representative study conducted in Spain and the relative risks were derived from a meta-analysis. AM point estimates are presented along with 95% confidence intervals (95% CI), calculated using a bootstrap naive procedure. AM, both overall and by smoking habit, was estimated for each combination of sex, age group, and cause of death (lung cancer and ischemic heart disease). A sensitivity analysis was performed. RESULTS A total of 747 (95% CI 676-825) deaths were attributable to ETS exposure, of which 279 (95% CI 256-306) were caused by lung cancer, and 468 (95% CI 417-523) by ischemic heart disease. Three-quarters (75.1%) of AM occurred in men and 60.9% in non-smokers. When chronic obstructive pulmonary disease and cerebrovascular disease are included, the burden of AM is estimated at 2242 deaths. CONCLUSIONS ETS exposure is associated with 1.5% of all deaths from lung cancer and ischemic heart disease in the population aged 35 and over. These data underline the need for health authorities to focus on reducing exposure to ETS in all settings and environments.
Collapse
|
4
|
de Marsillac PF, Cortez de Almeida RF, Machado CJ, Piraccini BM, Starace M, Tosti A, Vincenzi C, Kobzei K, Iorizzo M, Alves LD, Blanco A, Coelho C, Saceda-Corralo D, D'Atri G, Benez M, Ramos PM, Baja S, Tortelly VD, Frattini S, Melo DF. Clinical, epidemiological, trichoscopic and histopathological features of linear morphea on the scalp. J Eur Acad Dermatol Venereol 2022; 36:e892-e895. [PMID: 35694874 DOI: 10.1111/jdv.18323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 06/03/2022] [Indexed: 11/29/2022]
|
5
|
Llorenç V, Sainz-de-la-Maza M, García-Aparicio Á, Blanco A, Hernando-Hernández C, Cincunegui-Gutiérrez J, Fanlo P, Heras H, García-García O, Hernández-Garfella M, Veroz Gonzalez R, Rodriguez-Melian L, Jovani V. POS1331 CERTOLIZUMAB PEGOL IN UVEITIS. RETENTION PROBABILITY AND CAUSES OF DISCONTINUATION. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundA personalized disease-specific treatment for non-infectious uveitis (NIU) is challenging. Around 50% of adults with NIU who required classic DMARDs or adalimumab in clinical trials, failed at 6 months during open label phase [1,2]. Therefore, to investigate treatment alternatives for NIU are most needed.ObjectivesTo study Certolizumab pegol (CZP) retention rate (RR) at 24 months in NIU and susceptibility factors for discontinuation.MethodsAdults with NIU who received CZP for this indication were included. Data were gathered from the BioÚvea Spanish registry, detailed elsewhere[3]. Demographics, clinical, and therapeutic data was recorded from Nov 2016 to Nov 2017. The primary endpoint assessed was CZP RR at 24 months. Causes and susceptibility factors for definitive discontinuation of CZP were analyzed as well. CZP RR was calculated with the Kaplan-Meier method, Log-rank test was used for the univariate, and the Cox proportional hazard model was implemented for the multivariate analysis.ResultsThirty patients with a median of 41 (IQR 16) years, 18 (60%) females, were included. NIUs were bilateral in 19 (63%) patients and were active at CZP onset in 20 (71%). Half of the patients suffered from non-anterior NIUs, and etiologically 2 (7%) were unclassifiable, 7 (23%) had ocular syndromes, and 21 (70%) were associated to systemic disorders. Seven (23%) patients were bio-naïve, whereas 23 (77%) started CZP as a 2nd (5, 17%) or ≥ 3rd (18, 60%) biologic. With a median follow-up of 21.2 (Range 0.2 to 54.8) months, 12 (40%) patients discontinued CZP, 6 (20%) due to adverse events and 6 (20%) due to lack of efficacy. The overall CZP RR at 24 months was 53.6%, with a median Retention Time (RT) of 27.1 months. In the multivariate analysis, CZP started as a first biologic (HR 0.053, 95%CI 0.003 to 0.809; p = 0.035), and male gender (HR 0.1, 95%CI 0.015 to 0.694; p = 0.02) were protective factors for discontinuation. CZP RR at 24 months as a 1st line biologic was 100% with a median RT of 27.1 months. Conversely, CZP RR at 24 months as a ≥2nd line was 41.1% with a median RT of 17.1 months. When given as a 1st biologic, one (14%) patient discontinued CZP due to loss of efficacy at 27.1 months. Conversely, discontinuation of CZP when administered in ≥2nd line was more frequent, either due to lack or loss of efficacy in 5 (22%) patients or adverse events (AEs) in 6 (26%) (Figure 1).Figure 1.Retention rate of Certolizumab pegol in bio-naïve and bio-experienced patients with non-infectious uveitis.Abbreviations: DRT, Drug Retention Time; LTFU, lost to follow-up; DRR, Drug Retention Rate; PAR, Patients at Risk; AE, adverse event.ConclusionCZP in NIU showed an excellent retention rate at 24 months in bio-naïve patients. However, it was more than halved when CZP was started as a ≥2nd biologic. Discontinuation of CZP in bio-experienced patients was due to lack or loss of efficacy in 22% and to adverse events in an additional 26% of patients.References[1]Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. 2019;322(10):936-945.[2]Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375:932-943.[3]Llorenç V, Cordero-Coma M, Blanco-Esteban A, et al. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioUvea) Study Group. Ophthalmology. 2020;127(6):814-825.Disclosure of InterestsVictor Llorenç Speakers bureau: Optos, Alimera, Consultant of: AbbVie, Alimera, Allergan, UCB, Grant/research support from: AbbVie, Maite Sainz-de-la-Maza: None declared, Ángel García-Aparicio: None declared, Ana Blanco: None declared, Cristina Hernando-Hernández: None declared, Joseba Cincunegui-Gutiérrez: None declared, Patricia Fanlo: None declared, Henar Heras: None declared, Olga García-García: None declared, Marisa Hernández-Garfella: None declared, Raul Veroz Gonzalez: None declared, Luís Rodriguez-Melian: None declared, Vega Jovani: None declared
Collapse
|
6
|
Bañuelos Gimeno J, Blanco A, Díaz J, Linares C, López JA, Navas MA, Sánchez-Martínez G, Luna Y, Hervella B, Belda F, Culqui DR. Air pollution and meteorological variables' effects on COVID-19 first and second waves in Spain. INTERNATIONAL JOURNAL OF ENVIRONMENTAL SCIENCE AND TECHNOLOGY : IJEST 2022; 20:2869-2882. [PMID: 35529588 PMCID: PMC9065237 DOI: 10.1007/s13762-022-04190-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 03/18/2022] [Accepted: 04/10/2022] [Indexed: 06/14/2023]
Abstract
UNLABELLED The aim of this research is to study the influence of atmospheric pollutants and meteorological variables on the incidence rate of COVID-19 and the rate of hospital admissions due to COVID-19 during the first and second waves in nine Spanish provinces. Numerous studies analyze the effect of environmental and pollution variables separately, but few that include them in the same analysis together, and even fewer that compare their effects between the first and second waves of the virus. This study was conducted in nine of 52 Spanish provinces, using generalized linear models with Poisson link between levels of PM10, NO2 and O3 (independent variables) and maximum temperature and absolute humidity and the rates of incidence and hospital admissions of COVID-19 (dependent variables), establishing a series of significant lags. Using the estimators obtained from the significant multivariate models, the relative risks associated with these variables were calculated for increases of 10 µg/m3 for pollutants, 1 °C for temperature and 1 g/m3 for humidity. The results suggest that NO2 has a greater association than the other air pollution variables and the meteorological variables. There was a greater association with O3 in the first wave and with NO2 in the second. Pollutants showed a homogeneous distribution across the country. We conclude that, compared to other air pollutants and meteorological variables, NO2 is a protagonist that may modulate the incidence and severity of COVID-19, though preventive public health measures such as masking and hand washing are still very important. SUPPLEMENTARY INFORMATION The online version contains supplementary material available at 10.1007/s13762-022-04190-z.
Collapse
|
7
|
Marinello FG, Jiménez LM, Talavera E, Fraccalvieri D, Alberti P, Ostiz F, Frago R, Blanco A, Pellino G, Espín-Basany E. Percutaneous tibial nerve stimulation in patients with severe low anterior resection syndrome: randomized clinical trial. Br J Surg 2021; 108:380-387. [PMID: 33793754 DOI: 10.1093/bjs/znaa171] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 10/31/2020] [Accepted: 12/12/2020] [Indexed: 12/19/2022]
Abstract
BACKGROUND Treatment of low anterior resection syndrome (LARS) is challenging. Percutaneous tibial nerve stimulation (PTNS) can improve select bowel disorders. An RCT was conducted to assess the efficacy of PTNS compared with sham stimulation in patients with severe LARS. METHOD This was a multicentre, double-blind RCT. Patients with major LARS score were allocated to receive PTNS or sham therapy (needle placement simulation without nerve stimulation). The study included 16 sessions of 30 min once a week for 12 consecutive weeks, followed by four additional sessions once a fortnight for the following 4 weeks. The primary endpoint was efficacy of PTNS defined by the LARS score 12 months after treatment. Secondary endpoints included faecal incontinence, quality of life (QoL), and sexual function. RESULTS Between September 2016 and July 2018, 46 eligible patients were assigned randomly in a 1 : 1 ratio to PTNS or sham therapy. Baseline characteristics were similar. LARS scores were reduced in both groups, but only patients who received PTNS maintained the effect in the long term (mean(s.d.) score 36.4(3.9) at baseline versus 30.7(11.5) at 12 months; P = 0.018; effect size -5.4, 95 per cent c.i. -9.8 to -1.0), with a mean reduction of 15.7 per cent at 12-month follow-up. The faecal incontinence score was improved after 12 months in the PTNS group (mean(s.d.) score 15.4(5.2) at baseline versus 12.5(6.4) at 12 months; P = 0.018). No major changes in QoL and sexual function were observed in either group. There was no therapy-associated morbidity. Three patients discontinued the study, but none owing to study-related issues. CONCLUSION PTNS has positive effects in some patients with major LARS, especially in those with faecal incontinence. Registration number: NCT02517853 (http://www.clinicaltrials.gov).
Collapse
|
8
|
Herrero-Morant A, Martín-Varillas JL, Castañeda S, González-Mazón I, Maiz O, Blanco A, Sánchez J, Ortego N, Raya E, Olive A, Brandy-Garcia A, Prior-Español Á, Moriano C, Diez Alvarez E, Melero R, Graña J, Seijas-López Á, Urruticoechea-Arana A, Ramos Calvo A, Delgado Beltrán C, Loredo Martínez M, Salgado-Pérez E, Sivera F, Torre-Salaberri I, Narváez J, Andréu Sánchez JL, Martínez González O, Gómez de la Torre R, Fernández S, Romero-Yuste S, Espinosa G, González-Gay MÁ, Blanco R. POS1371 BIOLOGICAL THERAPY IN REFRACTORY NEUROBEHÇET’S DISEASE. MULTICENTER STUDY OF 42 PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Neuro-Behçet’s disease (NBD) is a severe complication of Behcet’s disease (BD). Despite well-established therapies with glucocorticoids and conventional immunosuppressants (cIS), a significant proportion of patients are refractory.Objectives:To assess efficacy and safety of biologic therapy (BT) in NBD refractory to glucocorticoids and at least one cIS.Methods:Open-label multicenter study of refractory NBD from 23 different referral Spanish Hospitals. Main outcome was neurological response. Secondarily, analytical efficacy was measured by Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Hemoglobin (Hb) at baseline, 6 months, 1 year and 2 years.Results:We studied 42 patients (21 women/ 21 men; mean age 40.4±10.8 years). HLA B51 was positive in 15 out of 37 (40.5%) patients tested. Non-neurological manifestations were oral ulcers (n=41, 97.6%), genital ulcers (n=31, 73.8%), skin lesions (n=28, 66.7%), arthralgia (n=27, 64.3%), uveitis (n=21, 50.0%), arthritis (n=9, 21.4%), venous thrombosis (n=9, 21.4%) and arterial thrombosis (n=4, 9.5%). The underlying neurologic manifestation were parenchymal (n=34, 81.0 %) and non-parenchymal (n=17, 40.5%) involvement (Table 1). The first BT used was infliximab (n=20), adalimumab (n=13), golimumab (n=3), tocilizumab (n=3) and etanercept (n=2).After 58.2±51.4 months since initiation of BT, neurological response was complete (n=27; 64.3%), or partial (n=11, 26.1%) (Figure 1). Only 4 (9.5%) patients did not respond. After 6 months of BT, ESR improved from.31.5±25.6 to 15.3±11.9 mm/h (p=0.005), CRP from 1.4 [0.2-12.8] to 0.3[0.1-3] mg/dL (p= 0.002) and Hb from 13.1±1.6 to 13.8±1.3 g/dL (p=0.005).Figure 1.Neurological clinical response to biological therapy.Primary failure was observed in 16 (38.1%) patients due to inefficacy (n=11, 68.8%) or adverse effects (n=5, 31.3%). Similarly, causes of secondary failure (n=6, 14.3%) were inefficacy (n=5, 83.3%) and adverse effects (n=1, 16.7%). No serious adverse effects were observed.Conclusion:BT, especially monoclonal anti-TNF drugs, seems to be effective and safe in refractory NBD.Table 1.Neurologic manifestation of 42 patients with refractory neurobehçet's disease treated with biologic therapy.Parenchymal subtype, n (%)34 (81.0)-Hemiparesis8 (19.1)-Polineuropathy8 (19.1)-Encephalopathy6 (14.3)-Cognitive impairments4 (9.5)-Optic neuropathy4 (9.5)-Ophtalmoparesis4 (9.5)-Other cranial nerve involvement3 (7.1)-Hemihypoesthesia3 (7.1)-Cerebellar dysphasia1 (2.4)-Cerebellar involvement1 (2.4)-Non-steroidal psicosis1 (2.4)Non-parenchymal subtype, n (%)17 (40.5)-Aseptic meningitis12(28.6)-Thrombosis4 (9.5)-Intracranial hypertension1 (2.4)Disclosure of Interests:Alba Herrero-Morant: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Lilly, Janssen, and Celgene, Santos Castañeda: None declared, Iñigo González-Mazón: None declared, Olga Maiz: None declared, Ana Blanco Speakers bureau: AbbVie, Julio Sánchez: None declared, Norberto Ortego: None declared, Enrique Raya Speakers bureau: MSD, Grant/research support from: AbbVie, Alejandro Olive: None declared, Anahy Brandy-Garcia: None declared, Águeda Prior-Español: None declared, Clara Moriano: None declared, Elvira Diez Alvarez: None declared, Rafael Melero: None declared, Jenaro Graña: None declared, Álvaro Seijas-López: None declared, ANA URRUTICOECHEA-ARANA: None declared, Angel Ramos Calvo: None declared, Concepción Delgado Beltrán: None declared, Marta Loredo Martínez: None declared, Eva Salgado-Pérez: None declared, Francisca Sivera: None declared, Ignacio Torre-Salaberri: None declared, J. Narváez Speakers bureau: Bristol-Myers Squibb, José Luis Andréu Sánchez: None declared, Olga Martínez González: None declared, Ricardo Gómez de la Torre: None declared, Sabela Fernández: None declared, Susana Romero-Yuste: None declared, Gerard Espinosa: None declared, Miguel Á. González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Sanofi, Lilly and MSD, Grant/research support from: AbbVie, MSD, and Roche
Collapse
|
9
|
Vegas-Revenga N, Martín-Varillas JL, Calvo-Río V, González-Mazón I, Sanchez-Bilbao L, Beltrán E, Fonollosa A, Maiz-Alonso O, Blanco A, Cordero-Coma M, Ortego N, Torre-Salaberri I, Francisco F, Muñoz Fernandez S, Esteban-Ortega MDM, Díaz-Llopis M, Cañal J, Ventosa JA, Demetrio-Pablo R, Domínguez L, Agudo-Bilbao M, Castañeda S, Ferraz-Amaro I, González-Gay MA, Blanco R. AB0771 HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT OF VISUAL ACUITY IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rapid and effective remission-inducing therapy is mandatory in uveitis to avoid irreversible structural and functional damage. In some severe cases biological agents might be required (1-6).High-dose intravenous methylprednisolone (IVMP) may achieve prompt control of inflammation in most immune mediated inflammatory diseases (IMID), including non-infectious uveitis (NIU).Objectives:To evaluate the efficacy and safety of IVMP pulse therapy in NIU of different IMID.Methods:Multicentre study of 71 patients with severe uveitis who received IVMP. The underlying diseases were: Vogt Koyanagy Harada disease (VKHD) (n=24), Behçet disease (BD) (19), Sarcoidosis (5) and idiopathic NIU (23). The main outcome variable was Best-Corrected Visual Acuity (BCVA) estimated using the Snellen chart. BCVA that was assessed at 0 (basal), 2-5, 7, 15 and 30 days after IVMP.The results are expressed as mean ±SD in normally distributed variables, or as median [IQR] when are not. Comparison of continuous variables was performed using the Wilcoxon test.Results:We studied 46♀/ 25♂ patients. The main features are shown in Table 1. IVMP dose ranged from 250 to 1000 mg/day administered for 3-5 consecutive days, the dose was established according to the presence or not of other systemic manifestations apart from uveitis. All of them had active intraocular inflammation at the moment of the study. BCVA values improved considerably after 1 month (Figure 1). No major side effects were observed.Figure 1.Improvement of best corrected visual acuity (BCVA).Conclusion:High-dose IVMP pulse therapy is useful and safe for a prompt control of BCVA regardless of the underlying IMID.References:[1]Vegas-Revenga N, et al. Am J Ophthalmol. 2019; 200:85-94. doi: 10.1016/j.ajo.2018.12.019[2]Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576[3]Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359[4]Atienza-Mateo B, et al. Rheumatology (Oxford) 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480.[5]Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026.[6]Martín-Varillas JL, et al. Ophthalmology. 2018;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020Table 1.Main features of 71 patients with NIU. Data are of affected eyes.VKHD(n=24)Idiophatic(n=23)Behcet’s disease (n=19)Sarcoidosis(n=5)Overall(n=71)Men/Women, n5/199/149/102/371Mean age (years) ±SD42 ±1147 ± 1533±1042 ± 22-Unilateral/Bilateral NIU, n (%)2 (8.3)/22(91.7)10 (43.5)/13(56.5)4 (21)/15 (79)3(60)/2(40)19/52NIU patterns, n (%) Posterior uveitis6 (25)9 (39.1)3 (15.8)1 (20)19 Panuveitis18 (75)14 (60.9)16 (84.2)4 (80)52Laboratory data, n (%) ANA2 (8.34)2 (8.7)0 (0)1 (20)5 HLA B270 (0)4 (17.4)0 (0)0 (0)4 HLA B290 (0)1 (4.3)0 (0)0 (0)1 HLA B510 (0)5 (21.7)8 (42)3 (60)16 Angiotensin Converting Enzyme (ACE)1 (4.17)2 (8.7)0 (0)1 (20)4Disclosure of Interests:None declared
Collapse
|
10
|
Fierro A, Pérez-Rojí G, Blanco A, López P, Andrés M, González-Quintanilla V, Pérez-Pereda S, Fontanillas N, Pascual J. Headache as main reason for consultation to a hospital Emergency Department in Spain: a prospective study. Neurologia 2021; 38:S0213-4853(21)00089-X. [PMID: 34083062 DOI: 10.1016/j.nrl.2021.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 03/28/2021] [Accepted: 03/28/2021] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION Headache is common in the general population and a frequent reason for medical consultation. OBJECTIVES To describe the characteristics of patients attending the Emergency Department (ED) for headache. METHODS A descriptive study with prospective collection of 100 consecutive patients over 15 years old who attended our ED due to headache as the main complaint. RESULTS Headache accounted for 1,4% of ED visits. The most common age range is between 31 and 45 years and the majority of the patients are females (61%). We diagnosed 67 primary and 33 secondary headaches. The most frequent diagnosis was migraine, with 36% of cases. One out of 3 patients had a history of headache and 4 out of 5 consulted by their own decision. Only a small percentage of patients were admitted as inpatients (12%), and 3 out of 5 were referred to Primary Care. Complementary tests were performed on 84% of the patients. One CT scan was performed for every 3 patients. A total of 80% patients was correctly diagnosed by the ED physicians. CONCLUSIONS Headache is a frequent complaint in the ED, where primary headaches are the most common with migraine being the most frequent reason for consultation. In our setting, there is a good screening and diagnosis of headaches, as well as an adequate use of the available resources in the ED for their diagnosis and management.
Collapse
|
11
|
Whitworth GL, Jaramillo-Fernandez J, Pariente JA, Garcia PD, Blanco A, Lopez C, Sotomayor-Torres CM. Simulations of micro-sphere/shell 2D silica photonic crystals for radiative cooling. OPTICS EXPRESS 2021; 29:16857-16866. [PMID: 34154238 DOI: 10.1364/oe.420989] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Accepted: 04/07/2021] [Indexed: 06/13/2023]
Abstract
Passive daytime radiative cooling has recently become an attractive approach to address the global energy demand associated with modern refrigeration technologies. One technique to increase the radiative cooling performance is to engineer the surface of a polar dielectric material to enhance its emittance at wavelengths in the atmospheric infrared transparency window (8-13 µm) by outcoupling surface-phonon polaritons (SPhPs) into free-space. Here we present a theoretical investigation of new surface morphologies based upon self-assembled silica photonic crystals (PCs) using an in-house built rigorous coupled-wave analysis (RCWA) code. Simulations predict that silica micro-sphere PCs can reach up to 73 K below ambient temperature, when solar absorption and conductive/convective losses can be neglected. Micro-shell structures are studied to explore the direct outcoupling of the SPhP, resulting in near-unity emittance between 8 and 10 µm. Additionally, the effect of material composition is explored by simulating soda-lime glass micro-shells, which, in turn, exhibit a temperature reduction of 61 K below ambient temperature. The RCWA code was compared to FTIR measurements of silica micro-spheres, self-assembled on microscope slides.
Collapse
|
12
|
Pitzonka L, Cutler M, Bu Y, Blanco A, Fumero E, Torra A, Smolinski M. 465 Tirbanibulin, a novel anti-proliferative and pro-apoptotic agent for the treatment of actinic keratosis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.489] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Blanco A, Larrinaga AR, Neto JM, Troncoso J, Méndez G, Domínguez-Lapido P, Ovejero A, Pereira L, Mouga TM, Gaspar R, Martínez B, Lemos MFL, Olabarria C. Spotting intruders: Species distribution models for managing invasive intertidal macroalgae. JOURNAL OF ENVIRONMENTAL MANAGEMENT 2021; 281:111861. [PMID: 33422911 DOI: 10.1016/j.jenvman.2020.111861] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2020] [Revised: 12/09/2020] [Accepted: 12/14/2020] [Indexed: 06/12/2023]
Abstract
Invasive macroalgae represent one of the major threats to marine biodiversity, ecosystem functioning and structure, as well as being important drivers of ecosystem services depletion. Many such species have become well established along the west coast of the Iberian Peninsula. However, the lack of information about the distribution of the invaders and the factors determining their occurrence make bioinvasions a difficult issue to manage. Such information is key to enabling the design and implementation of effective management plans. The present study aimed to map the current probability of presence of six invasive macroalgae: Grateloupia turuturu, Asparagopsis armata, Colpomenia peregrina, Sargassum muticum, Undaria pinnatifida, and Codium fragile ssp. fragile. For this purpose, an extensive field survey was carried out along the coast of the north-western Iberian Peninsula. Species distribution models (SDMs) were then used to map the presence probability of these invasive species throughout the study region on the basis of environmental and anthropogenic predictor variables. The southern Galician rias were identified as the main hotspots of macroalgal invasion, with a high probability of occurrence for most of the species considered. Conversely, the probability of presence on the Portuguese coast was generally low. Physico-chemical variables were the most important factors for predicting the distribution of invasive macroalgae contributing between 57.27 and 85.24% to the ensemble models. However, anthropogenic factors (including size of vessels, number of shipping lines, distance from ports, population density, etc.) considerably improved the estimates of the probability of occurrence for most of the target species. This study is one of the few to include anthropogenic factors in SDMs for invasive macroalgae. The findings suggest that management actions aimed at controlling these species should strengthen control and surveillance at ports, particularly in southern Galician rias. Early detection should be of main concern for risk assessment plans on the Portuguese coast.
Collapse
|
14
|
Blanco A, Rocha-de-Lossada C, Navarro P, Lerner SF, Perrone L, Soler Ferrández FL. "White-puncture": A simple technique to prevent tearing of the anterior capsule during capsulorhexis in intumescent white cataracts. ARCHIVOS DE LA SOCIEDAD ESPANOLA DE OFTALMOLOGIA 2021; 96:97-101. [PMID: 32873477 DOI: 10.1016/j.oftal.2020.07.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 07/14/2020] [Accepted: 07/15/2020] [Indexed: 06/11/2023]
Abstract
In order to avoid radial tearing of the anterior capsule while performing continuous circular capsulorhexis (CCC) in a white intumescent cataract, called the "Argentinian flag sign" when CCC is associated with a previous capsular stain with trypan blue, an initial puncture of the anterior capsule is performed with a 30G needle as the first step of the surgical procedure, that means, prior to any previous aperture of the anterior chamber. This act seems to allow the pressure of the intracrystalline space and the pressure of the anterior chamber to be equalized, as the liquefied content of the intumescent white cataract is released into a presumably hermetic anterior chamber, avoiding the dreaded anterior capsular radial tear. This technique, called "white-puncture", has been used in 174 cases without any associated complications.
Collapse
|
15
|
Adamczewski-Musch J, Arnold O, Behnke C, Belounnas A, Belyaev A, Berger-Chen JC, Blanco A, Blume C, Böhmer M, Bordalo P, Chernenko S, Chlad L, Ciepal I, Deveaux C, Dreyer J, Epple E, Fabbietti L, Fateev O, Filip P, Fonte P, Franco C, Friese J, Fröhlich I, Galatyuk T, Garzón JA, Gernhäuser R, Golosov O, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Heinz T, Hennino T, Hlavac S, Höhne C, Holzmann R, Ierusalimov A, Ivashkin A, Kämpfer B, Karavicheva T, Kardan B, Koenig I, Koenig W, Kohls M, Kolb BW, Korcyl G, Kornakov G, Kornas F, Kotte R, Kugler A, Kunz T, Kurepin A, Kurilkin A, Kurilkin P, Ladygin V, Lalik R, Lapidus K, Lebedev A, Lopes L, Lorenz M, Mahmoud T, Maier L, Malige A, Mamaev M, Mangiarotti A, Markert J, Matulewicz T, Maurus S, Metag V, Michel J, Mihaylov DM, Morozov S, Müntz C, Münzer R, Naumann L, Nowakowski K, Parpottas Y, Pechenov V, Pechenova O, Petukhov O, Piasecki K, Pietraszko J, Przygoda W, Pysz K, Ramos S, Ramstein B, Rathod N, Reshetin A, Rodriguez-Ramos P, Rosier P, Rost A, Rustamov A, Sadovsky A, Salabura P, Scheib T, Schuldes H, Schwab E, Scozzi F, Seck F, Sellheim P, Selyuzhenkov I, Siebenson J, Silva L, Singh U, Smyrski J, Sobolev YG, Spataro S, Spies S, Ströbele H, Stroth J, Sturm C, Svoboda O, Szala M, Tlusty P, Traxler M, Tsertos H, Usenko E, Wagner V, Wendisch C, Wiebusch MG, Wirth J, Wójcik D, Zanevsky Y, Zumbruch P. Directed, Elliptic, and Higher Order Flow Harmonics of Protons, Deuterons, and Tritons in Au+Au Collisions at sqrt[s_{NN}]=2.4 GeV. PHYSICAL REVIEW LETTERS 2020; 125:262301. [PMID: 33449792 DOI: 10.1103/physrevlett.125.262301] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 10/07/2020] [Accepted: 11/29/2020] [Indexed: 06/12/2023]
Abstract
Flow coefficients v_{n} of the orders n=1-6 are measured with the High-Acceptance DiElectron Spectrometer (HADES) at GSI for protons, deuterons, and tritons as a function of centrality, transverse momentum, and rapidity in Au+Au collisions at sqrt[s_{NN}]=2.4 GeV. Combining the information from the flow coefficients of all orders allows us to construct for the first time, at collision energies of a few GeV, a multidifferential picture of the angular emission pattern of these particles. It reflects the complicated interplay between the effect of the central fireball pressure on the emission of particles and their subsequent interaction with spectator matter. The high precision information on higher order flow coefficients is a major step forward in constraining the equation of state of dense baryonic matter.
Collapse
|
16
|
Salabura P, Adamczewski-Musch J, Arnoldi-Meadows B, Belounnas A, Belyaev A, Blanco A, Blume C, Böhmer M, Borisenko S, Chlad L, Chudoba P, Ciepał I, Dittert D, Dreyer J, Esmail W, Dürr M, Fabbietti L, Fateev S, Fonte P, Friese J, Fröhlich I, Förtsch J, Galatyuk T, Gernhäuser R, Golosov O, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Hensch R, Höhne C, Holzmann R, Huck H, Ierusalimov A, Ivashkin A, Kämpfer B, Kampert KH, Kardan B, Koenig I, Koenig W, Kornakov G, Kornas F, Kotte R, Kozela A, Kres I, Kuboś J, Kugler A, Kulesa P, Ladygin V, Lalik R, Lebedev A, Lebedev S, Linev S, Lopes L, Lorenz M, Lykasov G, Mahmoud T, Malige A, Markert J, Matulewicz T, Maurus S, Metag V, Michel J, Morozov S, Müntz C, Naumann L, Nowakowski K, Otto JH, Patel V, Pauly C, Pechenov V, Pechenova O, Petukhov O, Pfeifer D, Piasecki K, Pietraszko J, Prozorov A, Przygoda W, Pysz K, Ramstein B, Rathod N, Reshetin A, Ritman L, Rodriguez-Ramos P, Rost A, Salabura P, Scozzi F, Seck F, Selyuzhenkov I, Shabanov I, Singh US, Smyrski J, Spies S, Ströbele H, Stroth J, Stumm J, Svoboda O, Szala M, Tlusty P, Traxler M, Ungethüm C, Vazquez-Doce O, Wagner V, Weber A, Wendisch C, Wiebusch M, Wintz P, Wirth J, Zhilin A, Zumbruch P. Exploring time like tranistions in pp, πp and AA reactions with HADES. EPJ WEB OF CONFERENCES 2020. [DOI: 10.1051/epjconf/202024101013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Radiative transition of an excited baryon to a nucleon with emission of a virtual massive photon converting to dielectron pair (Dalitz decays) provides important information about baryon-photon coupling at low q2 in timelike region. A prominent enhancement in the respective electromagnetic transition Form Factors (etFF) at q2 near vector mesons ρ/ω poles has been predicted by various calculations reflecting strong baryon-vector meson couplings. The understanding of these couplings is also of primary importance for the interpretation of the emissivity of QCD matter studied in heavy ion collisions via dilepton emission. Dedicated measurements of baryon Dalitz decays in proton-proton and pion-proton scattering with HADES detector at GSI/FAIR are presented and discussed. The relevance of these studies for the interpretation of results obtained from heavy ion reactions is elucidated on the example of the HADES results.
Collapse
|
17
|
Aab A, Abreu P, Aglietta M, Albury JM, Allekotte I, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Alves Batista R, Anastasi GA, Anchordoqui L, Andrada B, Andringa S, Aramo C, Araújo Ferreira PR, Asorey H, Assis P, Avila G, Badescu AM, Bakalova A, Balaceanu A, Barbato F, Barreira Luz RJ, Becker KH, Bellido JA, Berat C, Bertaina ME, Bertou X, Biermann PL, Bister T, Biteau J, Blanco A, Blazek J, Bleve C, Boháčová M, Boncioli D, Bonifazi C, Bonneau Arbeletche L, Borodai N, Botti AM, Brack J, Bretz T, Briechle FL, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora KS, Caccianiga L, Calcagni L, Cancio A, Canfora F, Caracas I, Carceller JM, Caruso R, Castellina A, Catalani F, Cataldi G, Cazon L, Cerda M, Chinellato JA, Choi K, Chudoba J, Chytka L, Clay RW, Cobos Cerutti AC, Colalillo R, Coleman A, Coluccia MR, Conceição R, Condorelli A, Consolati G, Contreras F, Convenga F, Covault CE, Dasso S, Daumiller K, Dawson BR, Day JA, de Almeida RM, de Jesús J, de Jong SJ, De Mauro G, de Mello Neto JRT, De Mitri I, de Oliveira J, de Oliveira Franco D, de Souza V, De Vito E, Debatin J, Del Río M, Deligny O, Dembinski H, Dhital N, Di Giulio C, Di Matteo A, Díaz Castro ML, Dobrigkeit C, D'Olivo JC, Dorosti Q, Dos Anjos RC, Dova MT, Ebr J, Engel R, Epicoco I, Erdmann M, Escobar CO, Etchegoyen A, Falcke H, Farmer J, Farrar G, Fauth AC, Fazzini N, Feldbusch F, Fenu F, Fick B, Figueira JM, Filipčič A, Fodran T, Freire MM, Fujii T, Fuster A, Galea C, Galelli C, García B, Garcia Vegas AL, Gemmeke H, Gesualdi F, Gherghel-Lascu A, Ghia PL, Giaccari U, Giammarchi M, Giller M, Glombitza J, Gobbi F, Gollan F, Golup G, Gómez Berisso M, Gómez Vitale PF, Gongora JP, González N, Goos I, Góra D, Gorgi A, Gottowik M, Grubb TD, Guarino F, Guedes GP, Guido E, Hahn S, Halliday R, Hampel MR, Hansen P, Harari D, Harvey VM, Haungs A, Hebbeker T, Heck D, Hill GC, Hojvat C, Hörandel JR, Horvath P, Hrabovský M, Huege T, Hulsman J, Insolia A, Isar PG, Johnsen JA, Jurysek J, Kääpä A, Kampert KH, Keilhauer B, Kemp J, Klages HO, Kleifges M, Kleinfeller J, Köpke M, Kukec Mezek G, Lago BL, LaHurd D, Lang RG, Leigui de Oliveira MA, Lenok V, Letessier-Selvon A, Lhenry-Yvon I, Lo Presti D, Lopes L, López R, Lorek R, Luce Q, Lucero A, Machado Payeras A, Malacari M, Mancarella G, Mandat D, Manning BC, Manshanden J, Mantsch P, Marafico S, Mariazzi AG, Mariş IC, Marsella G, Martello D, Martinez H, Martínez Bravo O, Mastrodicasa M, Mathes HJ, Matthews J, Matthiae G, Mayotte E, Mazur PO, Medina-Tanco G, Melo D, Menshikov A, Merenda KD, Michal S, Micheletti MI, Miramonti L, Mockler D, Mollerach S, Montanet F, Morello C, Mostafá M, Müller AL, Muller MA, Mulrey K, Mussa R, Muzio M, Namasaka WM, Nellen L, Nguyen PH, Niculescu-Oglinzanu M, Niechciol M, Nitz D, Nosek D, Novotny V, Nožka L, Nucita A, Núñez LA, Palatka M, Pallotta J, Panetta MP, Papenbreer P, Parente G, Parra A, Pech M, Pedreira F, Pȩkala J, Pelayo R, Peña-Rodriguez J, Perez Armand J, Perlin M, Perrone L, Peters C, Petrera S, Pierog T, Pimenta M, Pirronello V, Platino M, Pont B, Pothast M, Privitera P, Prouza M, Puyleart A, Querchfeld S, Rautenberg J, Ravignani D, Reininghaus M, Ridky J, Riehn F, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Fernandez G, Rodriguez Rojo J, Roncoroni MJ, Roth M, Roulet E, Rovero AC, Ruehl P, Saffi SJ, Saftoiu A, Salamida F, Salazar H, Salina G, Sanabria Gomez JD, Sánchez F, Santos EM, Santos E, Sarazin F, Sarmento R, Sarmiento-Cano C, Sato R, Savina P, Schäfer C, Scherini V, Schieler H, Schimassek M, Schimp M, Schlüter F, Schmidt D, Scholten O, Schovánek P, Schröder FG, Schröder S, Schulz A, Sciutto SJ, Scornavacche M, Shellard RC, Sigl G, Silli G, Sima O, Šmída R, Sommers P, Soriano JF, Souchard J, Squartini R, Stadelmaier M, Stanca D, Stanič S, Stasielak J, Stassi P, Streich A, Suárez-Durán M, Sudholz T, Suomijärvi T, Supanitsky AD, Šupík J, Szadkowski Z, Taboada A, Tapia A, Timmermans C, Tkachenko O, Tobiska P, Todero Peixoto CJ, Tomé B, Torralba Elipe G, Travaini A, Travnicek P, Trimarelli C, Trini M, Tueros M, Ulrich R, Unger M, Urban M, Vaclavek L, Vacula M, Valdés Galicia JF, Valiño I, Valore L, van Vliet A, Varela E, Vargas Cárdenas B, Vásquez-Ramírez A, Veberič D, Ventura C, Vergara Quispe ID, Verzi V, Vicha J, Villaseñor L, Vink J, Vorobiov S, Wahlberg H, Watson AA, Weber M, Weindl A, Wiencke L, Wilczyński H, Winchen T, Wirtz M, Wittkowski D, Wundheiler B, Yushkov A, Zapparrata O, Zas E, Zavrtanik D, Zavrtanik M, Zehrer L, Zepeda A, Ziolkowski M, Zuccarello F. Features of the Energy Spectrum of Cosmic Rays above 2.5×10^{18} eV Using the Pierre Auger Observatory. PHYSICAL REVIEW LETTERS 2020; 125:121106. [PMID: 33016715 DOI: 10.1103/physrevlett.125.121106] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Accepted: 07/31/2020] [Indexed: 06/11/2023]
Abstract
We report a measurement of the energy spectrum of cosmic rays above 2.5×10^{18} eV based on 215 030 events. New results are presented: at about 1.3×10^{19} eV, the spectral index changes from 2.51±0.03(stat)±0.05(syst) to 3.05±0.05(stat)±0.10(syst), evolving to 5.1±0.3(stat)±0.1(syst) beyond 5×10^{19} eV, while no significant dependence of spectral features on the declination is seen in the accessible range. These features of the spectrum can be reproduced in models with energy-dependent mass composition. The energy density in cosmic rays above 5×10^{18} eV is [5.66±0.03(stat)±1.40(syst)]×10^{53} erg Mpc^{-3}.
Collapse
|
18
|
Herrero Morant A, Álvarez Reguera C, Calvo del Rio V, Maíz Alonso O, Blanco A, Narváez J, Castañeda S, Vicente E, Romero-Yuste S, Demetrio-Pablo R, Urruticoechea-Arana A, García Serrano JL, Callejas Rubio JL, Ortego N, Sánchez J, Estrada P, Rua-Figueroa I, Martínez-López D, Martín-Varillas JL, González-Gay MÁ, Blanco R. SAT0523 BIOLOGICAL THERAPY IN REFRACTORY ATYPICAL OPTIC NEURITIS. MULTICENTER STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating and can be isolated or associated to different diseases including autoimmune diseases. If it is not treated, it can lead to devastating visual results. Conventional treatment includes systemic corticosteroids and conventional immunosuppressants (CIS).Objectives:Our aim was to assess the efficacy of biological therapy in atypical ON refractory to conventional treatment.Methods:Open-label multicenter study including 19 patients diagnosed with atypical ON refractory to systemic corticosteroids and at least one CIS. The main outcomes assessed were Best Corrected Visual Acuity (BCVA) and optic nerve and ganglionar cells Optical Coherence Tomography (OCT). These outcome variables were recorded at baseline, 1 week, 2 weeks, 1 month, 3 months and 6 months and 1 year after biological therapy onset.FIGUREResults:We studied 19 patients (12 women/7 men); mean age of 34.8 ± 13.9 years. The underlying diseases were idiopathic (n=7), Behçet´s disease (n=5), systemic lupus erythematosus (n=2), neuromyelitis optica (n=3), sarcoidosis (n=1) and relapsing polychondritis (n=1)(TABLE).Before biological therapy and besides systemic corticosteroids, patients had received different CIS. Biological therapy was adalimumab (n=6), rituximab (n=6), infliximab (n=5) and tocilizumab (n=4). After biological therapy, an improvement in ocular parameters was observed: BCVA [0.7±0.3 to 0.8±0.3; p= 0.03], optic nerve OCT [123.2±58.3 to 190.5±175.4; p= 0.11], and ganglionar cells OCT [369.6±137.4 to 270.7±23.2; p= 0.03] at one year(FIGURE). After a mean follow-up of 29.1 ±19.2 months, there were no severe adverse effects observed.Conclusion:Biological therapy may be effective in patients with refractory atypical ON.TABLECaseGender/ AgeUnderlying diseaseLateralityIV steroids dose (g)Maximum prednisone oral dose (g)Conventional immunosuppressantsBiological therapyAdverse effects1F/29IdiopathicUnilateral460AZATCZNo2F/26IdiopathicBilateral5.530AZATCZNo3F/13IdiopathicBilateral-10MTXADANo4F/25IdiopathicBilateral460MTXIFX, TCZNo5F/24IdiopathicBilateral0.560MTX, AZAADANo6M/14IdiopathicBilateral-10MTXADANo7F/30Vasculitis ANCA+Unilateral360AZA, MMF, LFM, CFMRTXYes8M/21BehçetBilateral-60MTX, AZAADANausea Vomits9M/25BehçetUnilateral0.560MTX, CyAADANo10M/39BehçetUnilateral380MTX, MMFIFXNo11M/40BehçetUnilateral-80MMFIFXNo12M/37BehçetUnilateral-60CyAIFXNo13F/68NMOUnilateral2.530CFM, AZARTXNo14F/41NMOUnilateral360CFMRTXInfection15F/43NMOBilateral560AZARTXInfusion reaction16F/56SLEUnilateral-60HCQ, MMF, CFMRTXNo17F/47SLEUnilateral560HCQ, MMFRTXNo18F/43Relapsing polychondritisBilateral360MTX, CFMIFX, TCZNo19M/41SarcoidosisBilateral340AZAADANoDisclosure of Interests:Alba Herrero Morant: None declared, Carmen Álvarez Reguera: None declared, Vanesa Calvo del Rio Grant/research support from: MSD and Roche, Speakers bureau: Abbott, Lilly, Celgene, Grünenthal, UCB Pharma, Olga Maíz Alonso: None declared, Ana Blanco Speakers bureau: Abbvie, J. Narváez: None declared, Santos Castañeda: None declared, Esther Vicente Speakers bureau: BMS, Roche., Susana Romero-Yuste: None declared, Rosalía Demetrio-Pablo: None declared, ANA URRUTICOECHEA-ARANA: None declared, J. L. García Serrano: None declared, J. L. Callejas Rubio: None declared, Norberto Ortego: None declared, Julio Sánchez: None declared, Paula Estrada: None declared, Iñigo Rua-Figueroa: None declared, David Martínez-López: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Miguel Á. González-Gay Grant/research support from: AbbVie, MSD and Roche, Speakers bureau: AbbVie, MSD and Roche, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD
Collapse
|
19
|
Brennan K, Martin K, FitzGerald SP, O'Sullivan J, Wu Y, Blanco A, Richardson C, Mc Gee MM. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep 2020; 10:1039. [PMID: 31974468 PMCID: PMC6978318 DOI: 10.1038/s41598-020-57497-7] [Citation(s) in RCA: 422] [Impact Index Per Article: 105.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 12/16/2019] [Indexed: 12/31/2022] Open
Abstract
Extracellular vesicles (EVs) are nano-sized vesicles containing nucleic acid and protein cargo that are released from a multitude of cell types and have gained significant interest as potential diagnostic biomarkers. Human serum is a rich source of readily accessible EVs; however, the separation of EVs from serum proteins and non-EV lipid particles represents a considerable challenge. In this study, we compared the most commonly used isolation techniques, either alone or in combination, for the isolation of EVs from 200 µl of human serum and their separation from non-EV protein and lipid particles present in serum. The size and yield of particles isolated by each method was determined by nanoparticle tracking analysis, with the variation in particle size distribution being used to determine the relative impact of lipoproteins and protein aggregates on the isolated EV population. Purification of EVs from soluble protein was determined by calculating the ratio of EV particle count to protein concentration. Finally, lipoprotein particles co-isolated with EVs was determined by Western blot analysis of lipoprotein markers APOB and APOE. Overall, this study reveals that the choice of EV isolation procedure significantly impacts EV yield from human serum, together with the presence of lipoprotein and protein contaminants.
Collapse
|
20
|
Olszewska DA, Fallon EM, Pastores GM, Murphy K, Blanco A, Lynch T, Murphy SM. Autosomal Dominant Gene Negative Frontotemporal Dementia-Think of SCA17. THE CEREBELLUM 2019; 18:654-658. [PMID: 30617627 DOI: 10.1007/s12311-018-0998-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
SCA 17 is a rare, autosomal dominant disorder caused by TBP gene CAG/CAA repeat expansion. Ataxia and dementia are common. The presence of frontal dysfunction at outset of the disease may mimic frontotemporal dementia (FTD). Parkinsonism, chorea, dystonia, and pyramidal signs may occur. We report an Irish family with autosomal dominant partially penetrant frontal dementia with cerebellar atrophy due to SCA17 and present detailed neuropsychological assessment for the first time. A 44-year-old doctor presented with 18-month history of behavioral problems. She slowed down, became apathetic, and unable to multitask. She became more irritable and short tempered, and her work performance deteriorated. Brain MRI showed cerebellar atrophy and cerebellar hypometabolism was noted on FDG-PET. A sister developed personality changes at age 45 with apathy, and had problems with memory and social skills; another sister at age 39 became dysarthric and unsteady. A brother at age 52 demonstrated emotional lability, and became dysarthric, unsteady, and slowed down. Their mother aged 73 had an abnormal antalgic gait due to arthritis; their father was jocular and disinhibited. MAPT testing detected an exon 9 c.726C>T variant in the proband. Subsequent testing in nine siblings and both parents failed to show co-segregation with disease. SCA17 testing revealed a TBP gene 43 repeat expansion that co-segregated in all affected siblings and in the mother whose gait problems were initially attributed to arthritis. In over 80% of cases of FTD with clear autosomal dominant inheritance, causative gene defects involve MAPT, GRN, or C9orf72 mutations. A minority involves VCP, FUS, and CHMP2B. As evident from our case, SCA17 testing should also be considered, especially if cerebellar atrophy if found on imaging. Segregation analysis is crucial. MAPT variant (c.726C>T exon 9) detected in the family was deemed a polymorphism.
Collapse
|
21
|
Aab A, Abreu P, Aglietta M, Albuquerque I, Albury J, Allekotte I, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Anastasi G, Anchordoqui L, Andrada B, Andringa S, Aramo C, Asorey H, Assis P, Avila G, Badescu A, Bakalova A, Balaceanu A, Barbato F, Barreira Luz R, Baur S, Becker K, Bellido J, Berat C, Bertaina M, Bertou X, Biermann P, Biteau J, Blaess S, Blanco A, Blazek J, Bleve C, Boháčová M, Boncioli D, Bonifazi C, Borodai N, Botti A, Brack J, Bretz T, Bridgeman A, Briechle F, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora K, Caccianiga L, Calcagni L, Cancio A, Canfora F, Carceller J, Caruso R, Castellina A, Catalani F, Cataldi G, Cazon L, Cerda M, Chinellato J, Chudoba J, Chytka L, Clay R, Cobos Cerutti A, Colalillo R, Coleman A, Coluccia M, Conceição R, Condorelli A, Consolati G, Contreras F, Convenga F, Cooper M, Coutu S, Covault C, Daniel B, Dasso S, Daumiller K, Dawson B, Day J, de Almeida R, de Jong S, De Mauro G, de Mello Neto J, De Mitri I, de Oliveira J, de Oliveira Salles F, de Souza V, Debatin J, del Río M, Deligny O, Dhital N, Díaz Castro M, Diogo F, Dobrigkeit C, D’Olivo J, Dorosti Q, dos Anjos R, Dova M, Dundovic A, Ebr J, Engel R, Erdmann M, Escobar C, Etchegoyen A, Falcke H, Farmer J, Farrar G, Fauth A, Fazzini N, Feldbusch F, Fenu F, Ferreyro L, Figueira J, Filipčič A, Freire M, Fujii T, Fuster A, García B, Gemmeke H, Gherghel-Lascu A, Ghia P, Giaccari U, Giammarchi M, Giller M, Głas D, Glombitza J, Gobbi F, Golup G, Gómez Berisso M, Gómez Vitale P, Gongora J, González N, Goos I, Góra D, Gorgi A, Gottowik M, Grubb T, Guarino F, Guedes G, Guido E, Halliday R, Hampel M, Hansen P, Harari D, Harrison T, Harvey V, Haungs A, Hebbeker T, Heck D, Heimann P, Hill G, Hojvat C, Holt E, Homola P, Hörandel J, Horvath P, Hrabovský M, Huege T, Hulsman J, Insolia A, Isar P, Jandt I, Johnsen J, Josebachuili M, Jurysek J, Kääpä A, Kampert K, Keilhauer B, Kemmerich N, Kemp J, Klages H, Kleifges M, Kleinfeller J, Krause R, Kuempel D, Kukec Mezek G, Kuotb Awad A, Lago B, LaHurd D, Lang R, Legumina R, Leigui de Oliveira M, Lenok V, Letessier-Selvon A, Lhenry-Yvon I, Lippmann O, Lo Presti D, Lopes L, López R, López Casado A, Lorek R, Luce Q, Lucero A, Malacari M, Mancarella G, Mandat D, Manning B, Mantsch P, Mariazzi A, Mariş I, Marsella G, Martello D, Martinez H, Martínez Bravo O, Mastrodicasa M, Mathes H, Mathys S, Matthews J, Matthiae G, Mayotte E, Mazur P, Medina-Tanco G, Melo D, Menshikov A, Merenda KD, Michal S, Micheletti M, Middendorf L, Miramonti L, Mitrica B, Mockler D, Mollerach S, Montanet F, Morello C, Morlino G, Mostafá M, Müller A, Muller M, Müller S, Mussa R, Nellen L, Nguyen P, Niculescu-Oglinzanu M, Niechciol M, Nitz D, Nosek D, Novotny V, Nožka L, Nucita A, Núñez L, Olinto A, Palatka M, Pallotta J, Panetta M, Papenbreer P, Parente G, Parra A, Pech M, Pedreira F, Pȩkala J, Pelayo R, Peña-Rodriguez J, Pereira L, Perlin M, Perrone L, Peters C, Petrera S, Phuntsok J, Pierog T, Pimenta M, Pirronello V, Platino M, Poh J, Pont B, Porowski C, Prado R, Privitera P, Prouza M, Puyleart A, Querchfeld S, Quinn S, Ramos-Pollan R, Rautenberg J, Ravignani D, Reininghaus M, Ridky J, Riehn F, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Rojo J, Roncoroni M, Roth M, Roulet E, Rovero A, Ruehl P, Saffi S, Saftoiu A, Salamida F, Salazar H, Salina G, Sanabria Gomez J, Sánchez F, Santos E, Santos E, Sarazin F, Sarmento R, Sarmiento-Cano C, Sato R, Savina P, Schauer M, Scherini V, Schieler H, Schimassek M, Schimp M, Schlüter F, Schmidt D, Scholten O, Schovánek P, Schröder F, Schröder S, Schumacher J, Sciutto S, Scornavacche M, Shellard R, Sigl G, Silli G, Sima O, Šmída R, Snow G, Sommers P, Soriano J, Souchard J, Squartini R, Stanca D, Stanič S, Stasielak J, Stassi P, Stolpovskiy M, Streich A, Suarez F, Suárez-Durán M, Sudholz T, Suomijärvi T, Supanitsky A, Šupík J, Szadkowski Z, Taboada A, Taborda O, Tapia A, Timmermans C, Todero Peixoto C, Tomé B, Torralba Elipe G, Travaini A, Travnicek P, Trini M, Tueros M, Ulrich R, Unger M, Urban M, Valdés Galicia J, Valiño I, Valore L, van Bodegom P, van den Berg A, van Vliet A, Varela E, Vargas Cárdenas B, Veberič D, Ventura C, Vergara Quispe I, Verzi V, Vicha J, Villaseñor L, Vink J, Vorobiov S, Wahlberg H, Watson A, Weber M, Weindl A, Wiedeński M, Wiencke L, Wilczyński H, Winchen T, Wirtz M, Wittkowski D, Wundheiler B, Yang L, Yushkov A, Zas E, Zavrtanik D, Zavrtanik M, Zehrer L, Zepeda A, Zimmermann B, Ziolkowski M, Zong Z, Zuccarello F. Data-driven estimation of the invisible energy of cosmic ray showers with the Pierre Auger Observatory. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.100.082003] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
22
|
Ciruela P, Broner S, Izquierdo C, Pallarés R, Muñoz-Almagro C, Hernández S, Grau I, Domínguez A, Jané M, Ciruela P, Izquierdo C, Broner S, Hernández S, Jané M, Muñoz-Almagro C, Esteva C, de Sevilla M, Henares D, Pallarés R, Ardanuy C, Grau I, Marco F, Margall N, González-Cuevas A, Díaz A, Martin M, Llaberia J, Curriu M, Gallés C, Capdevila E, Gassiot P, Martínez-Zurita M, Martí C, Morta M, Sauca G, Gassós A, Sanfeliu E, Ballester F, Pujol I, Olsina M, Raga X, Gómez-Bertomeu F, Pérez-Moreno M, Vilamala A, Navarro M, Ribelles M, Garcia M, Padilla E, Prim N, Fontanals D, Sanfeliu I, Benitez M, Jou E, Sanjosé C, Giménez M, Quesada M, de la Fuente J, Calderon A, Ayala P, Vega L, Pérez-Jové J, Blanco A, Balado C, Valle I, Bastida M, Gonzalez-Moreno O, Ubanell A, Fenoll A, Yuste J. Indirect effects of paediatric conjugate vaccines on invasive pneumococcal disease in older adults. Int J Infect Dis 2019; 86:122-130. [DOI: 10.1016/j.ijid.2019.06.030] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 06/28/2019] [Accepted: 06/30/2019] [Indexed: 12/29/2022] Open
|
23
|
Masana L, López-Miranda J, Civeira F, Reinares L, Maraver J, Plana N, Cuenca R, Sanchez D, Hernandez J, Andres R, Blanco A, Villamayor S. Evolocumab Is Mainly Prescribed In Fh Patients With/Without Atherosclerotic Cardiovascular Disease (Ascvd) In Lipid/Internal Medicine Units In Spain: A Retrospective, Observational Study (Retoss-Imu). Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
24
|
Adamczewski-Musch J, Arnold O, Atomssa ET, Behnke C, Belounnas A, Belyaev A, Berger-Chen JC, Biernat J, Blanco A, Blume C, Böhmer M, Chernenko S, Chlad L, Chudoba P, Ciepał I, Deveaux C, Dittert D, Dreyer J, Epple E, Fabbietti L, Fateev O, Fonte P, Franco C, Friese J, Fröhlich I, Galatyuk T, Garzón JA, Gernhäuser R, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Heinz T, Hennino T, Höhne C, Holzmann R, Ierusalimov A, Ivashkin A, Kämpfer B, Kardan B, Koenig I, Koenig W, Kolb BW, Korcyl G, Kornakov G, Kornas F, Kotte R, Kuboś J, Kugler A, Kunz T, Kurepin A, Kurilkin A, Kurilkin P, Ladygin V, Lalik R, Lapidus K, Lebedev A, Linev S, Lopes L, Lorenz M, Mahmoud T, Maier L, Malige A, Markert J, Maurus S, Metag V, Michel J, Mihaylov DM, Mikhaylov V, Morozov S, Müntz C, Münzer R, Naumann L, Nowakowski K, Parpottas Y, Pechenov V, Pechenova O, Petukhov O, Pietraszko J, Prozorov AP, Przygoda W, Ramstein B, Rathod N, Reshetin A, Rodriguez-Ramos P, Rost A, Sadovsky A, Salabura P, Scheib T, Schmidt-Sommerfeld K, Schuldes H, Schwab E, Scozzi F, Seck F, Sellheim P, Siebenson J, Silva L, Smyrski J, Spataro S, Spies S, Ströbele H, Stroth J, Strzempek P, Sturm C, Svoboda O, Szala M, Tlusty P, Traxler M, Tsertos H, Ungethüm C, Vázquez Doce O, Wagner V, Wendisch C, Wiebusch MG, Wirth J, Wójcik D, Zanevsky Y, Zumbruch P, Curceanu C, Piscicchia K, Scordo A. Strong Absorption of Hadrons with Hidden and Open Strangeness in Nuclear Matter. PHYSICAL REVIEW LETTERS 2019; 123:022002. [PMID: 31386541 DOI: 10.1103/physrevlett.123.022002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 04/29/2019] [Indexed: 06/10/2023]
Abstract
We present the first observation of K^{-} and ϕ absorption within nuclear matter by means of π^{-}-induced reactions on C and W targets at an incident beam momentum of 1.7 GeV/c studied with HADES at SIS18/GSI. The double ratio (K^{-}/K^{+})_{W}/(K^{-}/K^{+})_{C} is found to be 0.319±0.009(stat)_{-0.012}^{+0.014}(syst) indicating a larger absorption of K^{-} in heavier targets as compared to lighter ones. The measured ϕ/K^{-} ratios in π^{-}+C and π^{-}+W reactions within the HADES acceptance are found to be equal to 0.55±0.04(stat)_{-0.07}^{+0.06}(syst) and to 0.63±0.06(stat)_{-0.11}^{+0.11}(syst), respectively. The similar ratios measured in the two different reactions demonstrate for the first time experimentally that the dynamics of the ϕ meson in nuclear medium is strongly coupled to the K^{-} dynamics. The large difference in the ϕ production off C and W nuclei is discussed in terms of a strong ϕN in-medium coupling. These results are relevant for the description of heavy-ion collisions and the structure of neutron stars.
Collapse
|
25
|
Varela-Eirín M, Varela-Vázquez A, Blanco A, Caeiro JR, Mayán MD. Regulación de la plasticidad celular y senescencia en condrocitos articulares: conexina 43 como diana terapéutica para el tratamiento de la artrosis. REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL 2019. [DOI: 10.4321/s1889-836x2019000200003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|